Turkish pharmaceutical companies have failed to win the large number oforders they had expected for drugs from Iraq, which will spend about $220 million on importing medicines following permission for these imports from the United Nations, according to the Turkish Economic Press Agency's EBA newsletter.
Press reports in the Turkish capital, Ankara, say that French drugmakers have been successful in winning Iraqi orders because of political support from the French government. These companies had reportedly received orders from Iraq worth some $25 million as of early January, compared with just $1.5 million worth of orders going to Turkish companies.
Turkish businessmen have complained that while the French government had been busy negotiating long-term contracts with Iraq, the Turkish government had failed to make such contacts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze